Table of Contents
Advances in Pharmaceutics
Volume 2015, Article ID 363061, 7 pages
http://dx.doi.org/10.1155/2015/363061
Research Article

Formulation, Optimization, and Characterization of Repaglinide Loaded Nanocrystal for Diabetes Therapy

1Parul Institute of Pharmacy, Limda, Vadodara, Gujarat, India
2Government College of Pharmacy, Amravati, Maharashtra, India

Received 19 August 2014; Revised 3 December 2014; Accepted 3 December 2014

Academic Editor: Changyang Gong

Copyright © 2015 Gajanan Shinde et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. G. M. M. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation,” Diabetic Medicine, vol. 15, no. 7, pp. 539–553, 1998. View at Publisher · View at Google Scholar
  2. WHO Expert Committee on Diabetes Mellitus, “Second report,” Technical Report Series 646, WHO, Geneva, Switzerland, 1980. View at Google Scholar
  3. American Diabetes Association, “Economic consequences of diabetes mellitus in the U.S. in 1997,” Diabetes Care, vol. 21, no. 2, pp. 296–309, 1998. View at Publisher · View at Google Scholar
  4. T. Abhinov, A. S. A. Khan, Ashrafa, S. Parveen, and K. P. Samapth Kumar, “Diabetes epidemic in India: risk factors, symptoms and treatment,” Indian Journal of Research in Pharmacy and Biotechnology, vol. 1, no. 2, pp. 234–243, 2013. View at Google Scholar
  5. National Diabetes Data Group, “Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance,” Diabetes, vol. 28, no. 12, pp. 1039–1057, 1979. View at Publisher · View at Google Scholar
  6. D. W. Cooke and L. Plotnick, “Type 1 diabetes mellitus in pediatrics,” Pediatrics in Review, vol. 29, no. 11, pp. 374–385, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. R. H. Müller, S. Runge, V. Ravelli, W. Mehnert, A. F. Thünemann, and E. B. Souto, “Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals,” International Journal of Pharmaceutics, vol. 317, no. 1, pp. 82–89, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Merisko-Liversidge, G. G. Liversidge, and E. R. Cooper, “Nanosizing: a formulation approach for poorly-water-soluble compounds,” European Journal of Pharmaceutical Sciences, vol. 18, no. 2, pp. 113–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Shinde, K. S. Rajesh, B. Devang, G. Bangale, D. Umalkar, and G. Virag, “Current status of colloidal system (nano range),” International Journal of Drug Formulation and Research, vol. 2, no. 6, pp. 39–54, 2011. View at Google Scholar
  10. J. Salazar, A. Ghanem, R. H. Müller, and J. P. Möschwitzer, “Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 81, no. 1, pp. 82–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Sun, W. Tian, Y. Zhang, J. He, S. Mao, and L. Fang, “Effect of novel stabilizers—cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 8, no. 4, pp. 460–467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J.-U. A. H. Junghanns and R. H. Müller, “Nanocrystal technology, drug delivery and clinical applications,” International Journal of Nanomedicine, vol. 3, no. 3, pp. 295–309, 2008. View at Google Scholar · View at Scopus
  13. E. Che, X. Zheng, C. Sun, D. Chang, T. Jiang, and S. Wang, “Drug nanocrystals: a state of the art formulation strategy for preparing the poorly water-soluble drugs,” Asian Journal of Pharmaceutical Sciences, vol. 7, no. 2, pp. 85–95, 2012. View at Google Scholar · View at Scopus
  14. H. Banavath, K. S. Raju, M. T. Ansari, M. S. Ali, and G. Pattnaik, “Nanosuspension: an attempt to enhance bioavailability of poorly soluble drugs,” International Journal of Pharmaceutical Sciences and Research, vol. 1, no. 9, pp. 1–11, 2010. View at Google Scholar
  15. R. H. Müller and K. Peters, “Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique,” International Journal of Pharmaceutics, vol. 160, no. 2, pp. 229–237, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Katteboinaa, “Drug nanocrystals: a novel formulation approach for poorly solubledrugs,” International Journal of PharmTech Research, vol. 1, no. 3, pp. 682–694, 2009. View at Google Scholar · View at Scopus
  17. B. K. Nanjwade, G. K. Derkar, H. Bechra, and F. V. Manvi, “Nanosized technological approaches for the delivery of poorly water soluble drugs,” Iranian Journal of Pharmaceutical Sciences, vol. 6, no. 3, pp. 149–162, 2010. View at Google Scholar · View at Scopus
  18. J.-Y. Choi, J. Y. Yoo, H.-S. Kwak, B. U. Nam, and J. Lee, “Role of polymeric stabilizers for drug nanocrystal dispersions,” Current Applied Physics, vol. 5, no. 5, pp. 472–474, 2005. View at Publisher · View at Google Scholar
  19. Q. Fu, L. Kou, C. Gong et al., “Relationship between dissolution and bioavailability for nimodipine colloidal dispersions: the critical size in improving bioavailability,” International Journal of Pharmaceutics, vol. 427, no. 2, pp. 358–364, 2012. View at Publisher · View at Google Scholar
  20. J. Hecq, M. Deleers, D. Fanara, H. Vranckx, and K. Amighi, “Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine,” International Journal of Pharmaceutics, vol. 299, no. 1-2, pp. 167–177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Mauludin, R. H. Müller, and C. M. Keck, “Kinetic solubility and dissolution velocity of rutin nanocrystals,” European Journal of Pharmaceutical Sciences, vol. 36, no. 4-5, pp. 502–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Quan, K. Shi, H. Piao, N. Liang, D. Xia, and F. Cui, “A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability,” International Journal of Pharmaceutics, vol. 430, no. 1-2, pp. 366–371, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. D. K. Krishna and H. P. Rajesh, “Dissolution enhancement of albendazole through nanocrystal formulation,” Journal of Pharmacy and Bioallied Sciences, vol. 4, no. 5, pp. 62–63, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Lai, E. Pini, G. Angioni et al., “Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 79, no. 3, pp. 552–558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Mauludin, R. H. Müller, and C. M. Keck, “Development of an oral rutin nanocrystal formulation,” International Journal of Pharmaceutics, vol. 370, no. 1-2, pp. 202–209, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. N. G. Sahoo, M. Kakran, L. A. Shaal et al., “Preparation and characterization of quercetin nanocrystals,” Journal of Pharmaceutical Sciences, vol. 100, no. 6, pp. 2379–2390, 2011. View at Publisher · View at Google Scholar · View at Scopus